Taltz and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported only by a few people who take Taltz.

The phase IV clinical study analyzes which people take Taltz and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 20,976 people who have side effects while taking Taltz from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 16, 2022

20,976 people reported to have side effects when taking Taltz.
Among them, 3 people (0.01%) have Gastrointestinal inflammation.


What is Taltz?

Taltz has active ingredients of ixekizumab. eHealthMe is studying from 16,482 Taltz users for its effectiveness, alternative drugs and more.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 772 drugs and 511 conditions by eHealthMe.

Number of Taltz and Gastrointestinal inflammation reports submitted per year:

Could Taltz cause Gastrointestinal inflammation?

Time on Taltz when people have Gastrointestinal inflammation *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Gastrointestinal inflammation when taking Taltz *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Gastrointestinal inflammation when taking Taltz *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 50 %
  • 50-59: 0.0 %
  • 60+: 50 %

Common side effects people have besides Gastrointestinal inflammation *:

  1. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 1 person, 33.33%
  2. Megacolon (a very dilated colon): 1 person, 33.33%

Common conditions people have *:

  1. Psoriasis (immune-mediated disease that affects the skin): 2 people, 66.67%
  2. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Taltz and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Gastrointestinal inflammation and when was it recovered:

Expand to all the drugs that have ingredients of ixekizumab:

Alternative drugs to, pros and cons of Taltz:

Common Taltz side effects:

Browse all side effects of Taltz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Gastrointestinal inflammation treatments and more:

COVID vaccines that are related to Gastrointestinal inflammation:

Common drugs associated with Gastrointestinal inflammation:

All the drugs that are associated with Gastrointestinal inflammation:

Common conditions associated with Gastrointestinal inflammation:

All the conditions that are associated with Gastrointestinal inflammation:

How the study uses the data?

The study uses data from the FDA. It is based on ixekizumab (the active ingredients of Taltz) and Taltz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: